Tharimmune, Inc. (THAR)
| Market Cap | 4.45M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -9.32M |
| Shares Out | 11.74M |
| EPS (ttm) | -7.14 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 437,445 |
| Open | 0.379 |
| Previous Close | 0.370 |
| Day's Range | 0.371 - 0.390 |
| 52-Week Range | 0.344 - 31.500 |
| Beta | 1.66 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 20, 2024 |
About THAR
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minot... [Read more]
Financial Performance
Financial StatementsNews
Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)
Obtained rights from Washington University to develop and incorporate human HER2 directed antibodies Complements early pipeline of novel tunable "Knob domain" antibodies for HER2 & HER3 BRIDGEWATER, N...
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
Group includes leading experts in multiple disciplines including immunology, liver diseases, protein engineering, antibody drug conjugates and platform innovation BRIDGEWATER, NJ / ACCESSWIRE / April ...
Tharimmune to Present at the Emerging Growth Conference on March 7, 2024
Tharimmune invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference BRIDGEWATER, NJ / ACCESS...
Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate
Positive safety/tolerability profile achieved with TH104 showing self-resolving, mild side effect profile aligned with previous studies Phase 1 clinical trial compared oral transmucosal delivery of TH...
Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis
Phase 1 clinical trial dosing of first patient complete; primary objective to assess safety/tolerability and absolute bioavailability of TH104 Phase 1 study expected to be completed in 1Q24 with topli...
Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update
Phase 1 trial initiated to assess safety/tolerability and absolute bioavailability of TH104 with topline data expected in 2Q24 Planning well underway for Phase 2 of TH104 in primary biliary cholangiti...
Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients
Phase 1 ex-US trial in chronic liver disease patients in an open-label study showed a 33.3% decrease in 24-hour mean itching intensity score after a single dose TH104 was well tolerated with no unexpe...
Tharimmune, Inc. Announces Closing of $11 Million Public Offering
BRIDGEWATER, NJ / ACCESSWIRE / November 30, 2023 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidat...
Tharimmune, Inc. Announces Pricing of $10 Million Public Offering
BRIDGEWATER, NJ / ACCESSWIRE / November 27, 2023 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidat...
Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC)
Phase 1 ex-US trial achieved primary objective of predictable pharmacokinetic profiling with favorable safety and tolerability Company expects to engage FDA on Phase 2 trial design and expects topline...
Tharimmune Announces 1-for-25 Reverse Stock Split
BRIDGEWATER, NJ / ACCESSWIRE / November 17, 2023 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidat...
Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis
Expects completion and topline data of a Phase 2 clinical trial in chronic pruritis over approximately 12 months after aligning with FDA on trial design Seeking first approval in an orphan disease, PB...
Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.
Expects to launch and complete a Phase 1 trial in Q4 2023 Tharimmune to begin trading under new ticker, THAR, on Monday September 25, 2023 BRIDGEWATER, NJ / ACCESSWIRE / September 22, 2023 / Hillstrea...
Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis
Anticipate completion of Phase 1 & Phase 2 clinical trials in chronic pruritis over the next approximately 12 months
Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13
BRIDGEWATER, N.J., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting dru...
Hillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023
BRIDGEWATER, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug...
Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215
Collaboration adds multiple modular swappable antigen recognition regions to lead program, HSB-3215, a bispecific antibody targeting novel epitopes on HER2/HER3 receptors
Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics
Lead bispecific antibody, HSB-3215 designed to target novel conformational epitopes on high value validated targets, HER2 and HER3
Hillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian Cancers
Anti-HER2 and Anti-HER3 monoclonal antibodies designed to have a high drug-to-antibody ratio intended enhance the bystander killing effect and be effective against a number of epithelial tumors
Hillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly Anderson
Appointment to Enhance Board's Expertise Across Investments, Business Development and Capital Markets Appointment to Enhance Board's Expertise Across Investments, Business Development and Capital Mark...
Hillstream BioPharma Announces Closing of Public Offering of Common Stock
BRIDGEWATER, N.J., May 02, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug...
Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences
12th Drug Discovery Strategic Summit, being held May 3-4 in Boston, MA Sidoti Micro-Cap Virtual Conference, being held virtually on May 10-11 World Orphan Drug Congress, being held May 23-25 in Washin...
Hillstream BioPharma Announces Pricing of Public Offering
BRIDGEWATER, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting dru...
Hillstream BioPharma Announces Proposed Public Offering
BRIDGEWATER, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting dru...
Hillstream BioPharma Selects OncoBay Clinical to Advance Clinical and Regulatory Development for its Lead Drug Candidate HSB-1216, an Anti-Cancer Mechanism
OncoBay Clinical is a boutique clinical research organization (CRO) that is a subsidiary of the Moffitt Cancer Center and has extensive experience in oncology drug development OncoBay Clinical is a bo...